ArticleFrontiers in medicine2023
Skeletal standardized uptake values obtained using quantitative SPECT/CT for the detection of bone metastases in patients with lung adenocarcinoma.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 6 citations in OpenAlex.
- Comparison of Diagnostic Performance of Whole-Body 360° CZT Bone SPECT/CT and Planar Bone Scintigraphy in Detecting Bone Metastasis in Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical outcomes after SPECT/CT-guided dual medial branch block and radiofrequency ablation for cervical and thoracic facet pain.Interventional pain medicine · 2026Article
- Differentiating between benign and malignant bone lesions: The value of using SPECT/CT.Radiology case reports · 2026Article
- Diagnostic value of quantitative SPECT/CT integrated parameters for differentiating spinal tuberculosis from spinal metastases.Frontiers in oncology · 2026Article
- Establishment an early precise diagnosis model for bone metastasis in lung cancer based on driver gene types.American journal of cancer research · 2026Article
- The use of SPECT-CT in the evaluation of lumbar spine pathology - A Narrative Review.Brain & spine · 2026Review
- Quantification in bone SPECT/CT.Frontiers in nuclear medicine · 2026Review
- The value ofQuantitative imaging in medicine and surgery · 2025Article
- Radiomics based on multiple machine learning methods for diagnosing early bone metastases not visible on CT images.Skeletal radiology · 2025Article
- Quantification of [EJNMMI research · 2024Article
- Correlation between the maximum standard uptake value and mean Hounsfield unit on single-photon emission computed tomography-computed tomography to discriminate benign and metastatic lesions among patients with breast cancer.Asian spine journal · 2024Article
- Quantitative vs. Qualitative SPECT-CT Diagnostic Accuracy in Bone Lesion Evaluation-A Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- The diagnostic value of quantitative bone SPECT/CT in solitary undetermined bone lesions.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the utility of skeletal standardized uptake values (SUVs) obtained using quantitative single-photon emission computed tomography/computed tomography (SPECT/CT) in differentiating bone metastases from benign lesions, particularly in patients with lung adenocarcinoma. Methods: Patients with lung adenocarcinoma who had undergone whole-body Tc-99m methyl-diphosphonate ( Results: A total of 252 bone metastatic lesions, 140 benign bone lesions, and 199 normal vertebrae from 115 patients with lung adenocarcinoma were studied (48 males, 67 females, median age: 59 years). Metastatic lesions had a significantly higher SUVmax (23.85 ± 14.34) than benign lesions (9.67 ± 7.47) and normal vertebrae (6.19 ± 1.46; Conclusion: SUVmax of quantitative SPECT/CT is a useful index for distinguishing benign bone lesions from bone metastases in patients with lung adenocarcinoma, particularly in the diagnosis of CT-negative bone metastases, but other factors that may affect SUVmax should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.